Caveolin-1 (Cav-1) is emerging as more than a structural membrane protein in fatty liver biology. In this study, higher circulating Cav-1 tracked with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis in humans, while the same pattern appeared in methionine- and choline-deficient diet models and in lipopolysaccharide-stimulated macrophages. The signal is biologically coherent: once hepatocytes and innate immune cells enter a state of chronic metabolic stress, membrane scaffolding proteins can become active participants in lipid trafficking, inflammatory signaling, and tissue remodeling rather than passive bystanders.

A single molecular axis appears to connect these processes here. Cav-1 deficiency did not simply reduce fat staining in the liver; it shifted the entire metabolic-injury program away from progressive steatohepatitis and toward a less injurious state.

Human Serum Cav-1 Rose With Advanced Liver Disease

Serum Cav-1 was measured in healthy controls and in patients with MASLD-related cirrhosis. The biomarker was increased in the diseased group, placing Cav-1 squarely inside the clinical phenotype of advanced metabolic liver injury. The cohort details, including age, sex, ALT, AST, TBIL, DBIL, and albumin, were summarized in the study’s supplementary material, but the central clinical message is straightforward: circulating Cav-1 rose alongside the most severe human liver phenotype examined.

That observation matters because it supports the notion that Cav-1 is induced during ongoing metabolic and inflammatory stress, not merely during isolated lipid accumulation. In a disease defined by the interaction between fat deposition, oxidative injury, and immune activation, a marker that rises with cirrhosis may reflect a broader failure of lipid compartmentalization and membrane signaling control.

Loss of Cav-1 Blunted Steatosis, Injury, and Fibrosis in Mice

The animal data were more decisive. In MCD-induced MASLD mice, Cav-1 deletion substantially reduced hepatic steatosis, hepatocellular injury, inflammatory responses, and fibrosis. Histologic injury, NAS scoring, Sirius Red collagen deposition, and serum transaminases all pointed in the same direction. In parallel, Cav-1-silenced AML-12 hepatocytes accumulated less lipid after oleic acid and palmitic acid exposure, showing that the effect was not limited to the whole-animal inflammatory environment.

This was not a cosmetic change in staining intensity. The liver injury program itself was altered. Reduced steatosis likely lowered the substrate burden that feeds lipotoxic stress, while the muted inflammatory response would have limited secondary injury from recruited myeloid cells and inflammatory cytokines. In MASLD, those two layers reinforce each other; breaking either one can shift the disease course, and Cav-1 deficiency appears to disrupt both.

ACC Phosphorylation and ABCA1 Rewrote the Lipid Program

Mechanistically, the study identified two metabolic levers. First, Cav-1 deficiency enhanced the inhibitory phosphorylation of acetyl-CoA carboxylase (ACC), suppressing ACC catalytic activity without changing total ACC protein levels. This distinction is central. ACC is the rate-limiting enzyme in de novo lipogenesis, and phosphorylation can turn down fatty acid synthesis even when the protein remains present. In practical terms, the liver’s lipogenic machinery was being quieted at the activity level rather than the abundance level.

Second, Cav-1 loss increased hepatic ABCA1 expression, promoting cholesterol efflux and adaptive lipid redistribution between the liver and peripheral circulation. ABCA1 is a gatekeeper of cholesterol export, so higher expression provides a plausible escape route for excess hepatic sterol load. The combination of reduced lipogenesis and improved cholesterol handling offers a credible explanation for the lower neutral lipid burden seen in the Cav-1-deficient state.

This dual effect is important because MASLD rarely reflects one lipid defect in isolation. Hepatic fat accumulation reflects fatty acid synthesis, cholesterol trafficking, intracellular redistribution, and inflammatory feedback loops. Cav-1 sits upstream of those interacting nodes, which is why removing it produced a broad metabolic phenotype rather than a narrow biochemical shift.

Innate Immune Recruitment Fell as the Hepatic Microenvironment Shifted

The inflammatory readout changed in parallel with the metabolic one. Cav-1 deletion robustly reduced recruitment of proinflammatory monocytes and macrophages, along with neutrophils, in the liver. Flow cytometry and qRT-PCR supported a less inflammatory hepatic microenvironment, and the histology aligned with that finding.

A brief sentence captures the core result: the inflamed liver recruited fewer myeloid cells when Cav-1 was absent.

This likely reflects more than a secondary consequence of reduced fat burden. Membrane scaffolding proteins can shape receptor signaling, cytokine release, and leukocyte trafficking, all of which influence how strongly the liver advertises injury to circulating immune cells. If Cav-1 helps establish the chemotactic and inflammatory tone of the steatotic liver, then its removal would be expected to blunt recruitment before immune amplification becomes self-sustaining.

Why the Findings Matter for MASLD Biology

The study presents Cav-1 as an upstream coordinator of hepatic immunometabolic remodeling rather than a single-pathway modifier. That framing is useful because MASLD progression depends on the convergence of lipogenesis, cholesterol dysregulation, innate immune activation, and fibrogenic remodeling. By coordinating ACC inhibitory phosphorylation, ABCA1-mediated cholesterol trafficking, and inflammatory cell recruitment, Cav-1 appears to sit at a junction where metabolic stress is translated into tissue injury.

The mechanistic logic is appealing. Excess lipid synthesis feeds hepatocyte stress; stress amplifies danger signals; danger signals recruit myeloid cells; and recruited immune cells intensify injury and fibrogenesis. Cav-1 deficiency interrupted that sequence at multiple points, which helps explain why the phenotype extended from steatosis to inflammation and fibrosis.

A second concise point follows from the data: fibrosis fell when Cav-1 was removed.

That outcome suggests the pathway is not confined to early steatosis. It reaches into the tissue remodeling phase that defines clinically significant MASLD progression, making Cav-1 biologically relevant to the transition from fatty liver to steatohepatitis and scarring.

Therapeutic Questions Left Open by the Dataset

The study supports Cav-1 as a possible therapeutic target, but several practical questions remain before that idea can move beyond preclinical biology. The MCD model is useful for mechanistic work, yet it does not fully mirror the human metabolic context of obesity-linked MASLD. The human cohort was also limited to serum measurements and advanced disease, so the relationship between Cav-1 and earlier stages of MASLD was not established here.

Even with those constraints, the work delivers a coherent mechanistic map. Cav-1 rose with metabolic liver injury, and removing it improved lipid handling, reduced hepatocellular damage, lowered inflammatory recruitment, and diminished fibrosis. For a disease driven by intertwined metabolic and immune injury, a regulator that influences both arms deserves close attention in follow-up studies.

Source Identifier

This paper was published in Frontiers in Immunology and carries DOI 10.3389/fimmu.2026.1971138.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA